Table A1. Total estimated drug treatment cost and rankings.
| List price rank | Estimated treatment cost rank | Active substance | Form and strength of drug substance | Number of cycles (3 weeks) | Treatment duration | Estimated treatment price |
|---|---|---|---|---|---|---|
| 31 | 1 | Bevacizumab | Injection fluid 25mg/ml 0.15 ml | 15.1 | Mean TL | €174,399.68 |
| 5 | 2 | Bevacizumab | Concentrate for solution infusion 25mg/ml 16 ml | 15.1 | Mean TL | €51,836.10 |
| 2 | 3 | Trastuzumab emtansine | Powder for solution infusion 160 mg | 9.5 | Median TL | €44,505.75 |
| 28 | 4 | Everolimus | Dispersible tablet 5 mg | 8.0 | Mean TL | €31,207.25 |
| 12 | 5 | Trastuzumab | Powder for solution infusion 150 mg | 13.0 | Mean TL | €21,947.45 |
| 25 | 6 | Everolimus | Tablet 10 mg | 8.0 | Mean TL | €21,254.31 |
| 36 | 7 | Lapatinib | Tablet 250 mg | 15.0 | Median TL | €18,682.30 |
| 1 | 8 | Pertuzumab | Concentrate for solution infusion 30mg/ml 14 ml | 4.5 | Mean TL | €16,665.64 |
| 3 | 9 | Trastuzumab | Injection fluid 120mg/ml 5 ml | 13.0 | Mean TL | €16,286.10 |
| 7 | 10 | Thiotepa | Powder for solution infusion 100 mg | 7.6 | Assumption | €14,467.30 |
| 32 | 11 | Vinblastin | Injection fluid 1mg/ml 10 ml | 7.6 | Assumption | €10,175.00 |
| 6 | 12 | Doxorubicin | Concentrate for solution infusion 2mg/ml 25 ml | 4.3 | Median PFS | €9,950.96 |
| 11 | 13 | Eribulin | Injection fluid 0,44mg/ml 3 ml | 4.8 | Mean TL | €8,551.01 |
| 14 | 14 | Paclitaxel | Powder for solution infusion 100 mg | 5.6 | Mean TL | €8,024.00 |
| 10 | 15 | Doxorubicin | Powder for solution infusion 50 mg | 4.3 | Median PFS | €6,354.32 |
| 4 | 16 | Paclitaxel | Concentrate for solution infusion 6 mg/ml 100 ml | 5.6 | Mean TL | €6,152.86 |
| 16 | 17 | Fulvestrant | Injection fluid 50 mg/ml 5 ml | 8.7 | Median PFS | €5,490.16 |
| 8 | 18 | Docetaxel | Concentrate for solution infusion 10mg/ml 16 ml | 6.0 | Mean TL | €5,338.08 |
| 9 | 19 | Docetaxel | Concentrate for solution infusion 20mg/ml 8 ml | 6.0 | Mean TL | €5,264.81 |
| 38 | 20 | Fluorouracil | Crème 50mg/g 15 g | 6.0 | Mean TL | €4,136.00 |
| 21 | 21 | Gemcitabin | Powder for solution infusion 2000 mg | 8.2 | Mean DFS | €2,418.96 |
| 20 | 22 | Gemcitabin | Infusion fluid 10mg/ml 220 ml | 8.2 | Mean DFS | €2,277.94 |
| 13 | 23 | Epirubicin | Injection fluid 2mg/ml 100 ml | 7.6 | Assumption | €1,841.13 |
| 22 | 24 | Gemcitabin | Concentrate for solution infusion 100mg/ml 20 ml | 8.2 | Mean DFS | €1,824.52 |
| 17 | 25 | Epirubicin | Infusion fluid 2mg/ml 100 ml | 7.6 | Assumption | €1,561.51 |
| 19 | 26 | Mitoxantrone hydrochloride | Concentrate for solution infusion 2mg/ml 15 ml | 7.6 | Assumption | €1,486.01 |
| 29 | 27 | Vinorelbin | Capsule 30 mg | 4.0 | TTP | €1,371.22 |
| 27 | 28 | Vinorelbin | Concentrate for solution infusion 10mg/ml 5 ml | 4.0 | TTP | €1,272.71 |
| 24 | 29 | Pamidronate disodium |
Concentrate for solution infusion 9mg/ml 10 ml | 7.6 | Assumption | €1,109.25 |
| 39 | 30 | Megestrol | Tablet 160 mg | 7.6 | Assumption | €1,025.81 |
| 26 | 31 | Melphalan | Powder for solution infusion 50 mg | 7.6 | Assumption | €985.34 |
| 15 | 32 | Goserelin Acetate | Implantation stick 10.8 mg | 7.6 | Assumption | €865.92 |
| 18 | 33 | Doxorubicin | Injection fluid 2mg/ml 100 ml | 4.3 | Median PFS | €641.65 |
| 30 | 34 | Ibandronic acid | Injection fluid 1mg/ml 3ml | 7.6 | Assumption | €554.99 |
| 35 | 35 | Vincristine | Injection fluid 1mg/ml 2 ml | 7.6 | Assumption | €517.39 |
| 40 | 36 | Melphalan* | Tablet 2 mg | 7.6 | Assumption | €500.85 |
| 42 | 37 | Capecitabin | Tablet 500 mg | 4.4 | TTP | €339.55 |
| 33 | 38 | Cyclophosphamide | Powder injection fluid 2000 mg | 6.0 | Mean TL | €227.25 |
| 23 | 39 | Mitomycin C | Powder for injection fluid 40 mg | 7.6 | Assumption | €207.01 |
| 37 | 40 | Pamidronate disodium |
Infusion fluid 0,18mg/ml 500 ml | 7.6 | Assumption | €131.09 |
*
If an assumption was used to estimate the average treatment length, this assumption was based on the average treatment length of all other drugs for which a treatment length was available in the EPARs or ZINL assessment reports. Mean TL = Mean treatment length. median PFS = Median progression-free survival. TTP = Time to progression